PEN Q4 2021 Earnings — Penumbra, Inc. Revenue & Financial Results | Market Cap Arena

PENPenumbra, Inc.

$13B

Q4 2021 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$204M+22.2% YoY

Gross Profit

$125M61.5% margin

Operating Income

-$40M-19.6% margin

Net Income

-$25M-12.1% margin

EPS (Diluted)

$-0.66

QoQ Revenue Growth

+7.3%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$17M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$290M

Stockholders' Equity

$954M

Cash & Equivalents

$59M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$204M	$167M	+22.2%
Gross Profit	$125M	$94M	+33.0%
Operating Income	-$40M	-$2M	-2195.5%
Net Income	-$25M	$4M	-775.2%

Revenue Segments

Peripheral Vascular

$114M56%

Neuro

$90M44%

Geographic Segments

UNITED STATES

$144M71%

Other Non-US

$60M29%